Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Tg Therapeuticscmn (TGTX)
Tg Therapeuticscmn (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeuticscmn 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NY 27560 USA

www.tgtherapeutics.com P: 212-554-4484

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 1,919,879
Enterprise Value, $K 1,888,719
Shares Outstanding, K 151,410
Annual Sales, $ 2,790 K
Annual Net Income, $ -198,340 K
Last Quarter Sales, $ 165,820 K
Last Quarter Net Income, $ 113,930 K
EBIT, $ -18,940 K
EBITDA, $ -16,910 K
60-Month Beta 2.10
% of Insider Shareholders 9.20%
% of Institutional Shareholders 57.92%
Float, K 137,480
% Float 90.80%
Short Volume Ratio 0.39

Growth:

1-Year Return 58.27%
3-Year Return -55.89%
5-Year Return 152.60%
5-Year Revenue Growth 1,760.00%
5-Year Earnings Growth 23.56%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.73 on 11/01/23
Next Earnings Date N/A
Earnings Per Share ttm -0.28
EPS Growth vs. Prev Qtr 314.71%
EPS Growth vs. Prev Year 380.77%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 591.27
Price/Earnings to Growth N/A
Return-on-Equity % -35.58%
Return-on-Assets % -10.99%
Profit Margin % -7,108.96%
Net Margin % N/A
Debt/Equity 2.42
Price/Sales 695.34
Price/Cash Flow N/A
Price/Book 11.61
Book Value/Share 1.09
Interest Coverage -18.46
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar